Inhibition of antigen presentation by the glycine/alanine repeat domain is not conserved in simian homologues of Epstein-Barr virus nuclear antigen 1

Journal of Virology

Volumn 73, Issue 9, 1999, Pages 7381-7389

  Blake, Neil W ^a   Moghaddam, Amir ^b   Rao, Pasupuleti ^b   Kaur, Amitinder ^b   Glickman, Rhona ^b   Cho, Young Gyu ^b   Marchini, Andrew ^c   Haigh, Tracey ^a   Johnson, R Paul ^b   Rickinson, Alan B ^a   Wang, Fred ^b,d  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b HARVARD MEDICAL SCHOOL   (United States)

^c PRINCETON UNIVERSITY   (United States)

^d CHANNING LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; CELL NUCLEUS ANTIGEN; GLYCINE; VIRUS ANTIGEN;

ANIMAL CELL; ANTIGEN PRESENTATION; ARTICLE; BABOON; EPSTEIN BARR VIRUS; GENETIC CONSERVATION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; RHESUS MONKEY; SEQUENCE HOMOLOGY;

EID: 0032866173     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.73.9.7381-7389.1999     Document Type: Article

References (39)

1. Allen, T. M., J. Sidney, M. F. del Guercio, R. L. Glickman, G. L. Lensmeyer, D. A. Wiebe, R. DeMars, C. D. Pauza, R. P. Johnson, A. Sette, and D. I. Watkins. 1998. Characterization of the peptide binding motif of a rhesus MHC class I molecule (Mamu-A *01) that binds an immunodominant CTL epitope from simian immunodeficiency virus. J. Immunol. 160:6062-6071.
2. + T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity 7:791-802.
3. Blasco, R., and B. Moss. 1995. Selection of recombinant vaccinia viruses on the basis of plaque formation. Gene 158:157-162.
4. Falk, K., J. W. Gratama, M. Rowe, J. Z. Zou, F. Khanim, L. S. Young, M. A. Oosterveer, and I. Ernberg. 1995. The role of repetitive DNA sequences in the size variation of Epstein-Barr virus (EBV) nuclear antigens, and the identification of different EBV isolates using RFLP and PCR analysis. J. Gen. Virol. 76:779-790.
5. Franken, M., B. Annis, A. Ali, and F. Wang. 1995. 5′ coding and regulatory region sequence divergence with conserved function of the Epstein-Barr virus LMP2A homolog in herpesvirus papio. J. Virol. 69:8011-8019.
6. Franken, M., O. Devergne, M. Rosenzweig, B. Annis, E. Kieff, and F. Wang. 1996. Comparative analysis identifies conserved tumor necrosis factor receptor-associated factor 3 binding sites in the human and simian Epstein-Barr virus oncogene LMP1. J. Virol. 70:7819-7826.
7. Gratama, J. W., M. A. Oosterveer, F. E. Zwaan, J. Lepoutre, G. Klein, and I. Ernberg. 1988. Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: implications for sites of viral latency. Proc. Natl. Acad. Sci. USA 85:8693-8696.
8. Hardy, S., M. Kitamura, T. Harris-Stansil, Y. Dai, and M. L. Phipps. 1997. Construction of adenovirus vectors through Cre-lox recombination. J. Virol. 71:1842-1849.
9. Hengel, H., T. Flohr, G. J. Hammerling, U. H. Koszinowski, and F. Momburg. 1996. Human cytomegalovirus inhibits peptide translocation into the endoplasmic reticulum for MHC class I assembly. J. Gen. Virol. 77:2287-2296.
10. Izumi, K. M., K. M. Kaye, and E. D. Kieff. 1997. The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation. Proc. Natl. Acad. Sci. USA 94:1447-1452.
11. Izumi, K. M., and E. D. Kieff. 1997. The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kappaB. Proc. Natl. Acad. Sci. USA 94: 12592-12597.
12. Johnson, R. P., R. L. Glickman, J. Q. Yang, A. Kaur, J. T. Dion, M. J. Mulligan, and R. C. Desrosiers. 1997. Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus. J. Virol. 71:7711-7718.
13. Kaur, A., M. D. Daniel, D. Hempel, D. Lee-Parritz, M. S. Hirsch, and R. P. Johnson. 1996. Cytotoxic T-lymphocyte responses to cytomegalovirus in normal and simian immunodeficiency virus-infected rhesus macaques. J. Virol. 70:7725-7733.
14. Kay, R., and J. McPherson. 1987. Hybrid pUC vectors for addition of new restriction enzyme sites to the ends of DNA fragments. Nucleic Acids Res. 15:2778.
15. Lee, M. A., M. E. Diamond, and J. L. Yates. 1999. Genetic evidence that EBNA-1 is needed for efficient, stable latent infection by epstein-barr virus. J. Virol. 73:2974-2982.
16. Lee, S. P., C. M. Constandinou, W. A. Thomas, D. Croom-Carter, N. W. Blake, P. G. Murray, J. Crocker, and A. B. Rickinson. 1998. Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: analysis of the HLA class I processing pathway and the effects of interleukin-10 on Epstein-Barr virus-specific cytotoxic T-cell recognition. Blood 92:1020-1030.
17. Levitskaya, J., M. Coram, V. Levitsky, S. Imreh, P. M. Steigerwald-Mullen, G. Klein, M. G. Kurilla, and M. G. Masucci. 1995. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375:685-688.
18. Levitskaya, J., A. Sharipo, A. Leonchiks, A. Ciechanover, and M. G. Masucci. 1997. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc. Natl. Acad. Sci. USA 94:12616-12621.
19. Ling, P. D., J. J. Ryon, and S. D. Hayward. 1993. EBNA-2 of herpesvirus papio diverges significantly from the type A and type B EBNA-2 proteins of Epstein-Barr virus but retains an efficient transactivation domain with a conserved hydrophobic motif. J. Virol. 67:2990-3003.
20. Mackey, D., T. Middleton, and B. Sugden. 1995. Multiple regions within EBNA1 can link DNAs. J. Virol. 69:6199-6208.
21. Miller, M. D., H. Yamamoto, A. L. Hughes, D. I. Watkins, and N. L. Letvin. 1991. Definition of an epitope and MHC class I molecule recognized by gag-specific cytotoxic T lymphocytes in SIVmac-infected rhesus monkeys. J. Immunol. 147:320-329.
22. Miyashita, E. M., B. Yang, K. M. Lam, D. H. Crawford, and D. A. Thorley-Lawson. 1995. A novel form of Epstein-Barr virus latency in normal B cells in vivo. Cell 80:593-601.
23. Moghaddam, A., M. Rosenzweig, D. Lee-Parritz, B. Annis, R. P. Johnson, and F. Wang. 1997. An animal model for acute and persistent Epstein-Barr virus infection. Science 276:2030-2033.
24. Mukherjee, S., P. Trivedi, D. M. Dorfman, G. Klein, and A. Townsend. 1998. Murine cytotoxic T lymphocytes recognize an epitope in an EBNA-1 fragment, but fail to lyse EBNA-1-expressing mouse cells. J. Exp. Med. 187:445-450.
25. Murray, R. J., M. G. Kurilla, J. M. Brooks, W. A. Thomas, M. Rowe, E. Kieff, and A. B. Rickinson. 1992. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J. Exp. Med. 176:157-168.
26. Rabin, H., R. H. Neubauer, R. F. d. Hopkins, and M. Nonoyama. 1978. Further characterization of a herpesvirus-positive orangutan cell line and comparative aspects of in vitro transformation with lymphotropic old world primate herpesviruses. Int. J. Cancer 21:762-767.
27. Rangan, S. R., L. N. Martin, B. E. Bozelka, N. Wang, and B. J. Gormus. 1986. Epstein-Barr virus-related herpesvirus from a rhesus monkey (Macaca mulatta) with malignant lymphoma. Int. J. Cancer 38:425-432.
28. Rickinson, A. B., and E. Kieff. 1996. Epstein-Barr virus, p. 2397-2446. In D. Knipe, B. Fields, and P. Howley (ed.), Virology. Raven Press, Philadelphia, Pa.
29. Rowe, M., D. T. Rowe, C. D. Gregory, L. S. Young, P. J. Farrell, H. Rupani, and A. B. Rickinson. 1987. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J. 6:2743-2751.
30. Ruf, I. K., A. Moghaddam, F. Wang, and J. Sample. 1999. Mechanisms that regulate Epstein-Barr virus EBNA-1 gene transcription during restricted latency are conserved among lymphocryptoviruses of Old World primates. J. Virol. 73:1980-1989.
31. Sharipo, A., M. Imreh, A. Leonchiks, S. Imreh, and M. G. Masucci. 1998. A minimal glycine-alanine repeat prevents the interaction of ubiquitinated I KB α with the proteasome: a new mechanism for selective inhibition of proteolysis. Nat. Med. 4:939-944.
32. Smith, G. L. 1993. Gene expression by vaccinia virus vectors, p. 257-284. In A. Davison and R. Elliot (ed.), Molecular virology: a practical approach. IRL Press, Oxford, United Kingdom.
33. Sylla, B. S., S. C. Hung, D. M. Davidson, E. Hatzivassiliou, N. L. Malinin, D. Wallach, T. D. Gilmore, E. Kieff, and G. Mosialos. 1998. Epstein-Barr virus-transforming protein latent infection membrane protein 1 activates transcription factor NF-KB through a pathway that includes the NF-KB-inducing kinase and the IKB kinases IKKα and IKKβ. Proc. Natl. Acad. Sci. USA 95:10106-10111.
34. Tierney, R. J., N. Steven, L. S. Young, and A. B. Rickinson. 1994. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J. Virol. 68:7374-7385.
35. Wang, F., H. Jiang, P. Rivailler, P. Ling, A. Gordadze, and Y. Cho. Unpublished observations.
36. Wang, F., X. Li, B. Annis, and D. L. Faustman. 1995. Tap-1 and Tap-2 gene therapy selectively restores conformationally dependent HLA class I expression in type I diabetic cells. Hum. Gene Ther. 6:1005-1017.
37. Yao, Q. Y., P. Ogan, M. Rowe, M. Wood, and A. B. Rickinson. 1989. Epstein-Barr virus-infected B cells persist in the circulation of acyclovir-treated virus carriers. Int. J. Cancer 43:67-71.
38. Yates, J. L., S. M. Camiolo, S. Ali, and A. Ying. 1996. Comparison of the EBNA-1 proteins of Epstein-Barr virus and herpesvirus papio in sequence and function. Virology 222:1-13.
39. + T lymphocytes. Cell 77:525-535.